Bedford, MA (March 2017) — First Light Diagnostics (formerly First Light Biosciences), a developer of breakthrough automated diagnostic products for rapid, sensitive and cost-effective detection of Healthcare Associated Infections (HAI) today announced they had been selected as a semifinalist and awarded a $50,000 prize in the first phase (Step 1) of the Antimicrobial Resistance Diagnostic Challenge administered by the National Institutes of Health (NIH) and the Biomedical Advanced Research and Development Authority (BARDA).
According to the NIH website, “The prize is sponsored by two U.S. Department of Health and Human Services components, the National Institutes of Health and the Biomedical Advanced Research and Development Authority (BARDA) within the HHS Office of the Assistant Secretary for Preparedness and Response (ASPR), in support of the National Action Plan for Combating Antibiotic-Resistant Bacteria.”
About First Light Diagnostics
First Light Diagnostics is developing and preparing to commercialize, innovative diagnostic products for rapid, sensitive and cost-saving detection of life-threatening infections, and combating the spread of antibiotic resistance. Don Straus is the company’s Founder and primary inventor of the company’s core scientific technology. Based on its proprietary MultiPath™ detection technology, First Light’s products combine the clinical performance of the most advanced commercial laboratory tests with speed, cost-effectiveness, and ease-of-use. The tests rapidly detect infections, identify infectious agents, and determine effective targeted antibiotic therapy. This will improve patient outcomes, reduce healthcare costs, and prevent inappropriate use of powerful antibiotics. To learn more, please visit: www.firstlightidx.com